Corrigendum to “Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22” [Canc. Lett. 340 (1) (Oct 28, 2013) 72–81] (Cancer Letters (2013) 340(1) (72–81), (S0304383513004928), (10.1016/j.canlet.2013.06.027));Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22

Cancer Letters

Volumn 340, Issue 1, 2013, Pages 72-81

  Tang, Hailin ^a,b   Kong, Yanan ^a   Guo, Jiaoli ^a   Tang, Yi ^b   Xie, Xinhua ^a   Yang, Lu ^a   Su, Qi ^b   Xie, Xiaoming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Diallyl disulfide; Gastric cancer; MicroRNA; Wnt 1 signaling pathway

Indexed keywords

BETA CATENIN; DIALLYL DISULFIDE; MICRORNA; MICRORNA 138; MICRORNA 143; MICRORNA 150; MICRORNA 15B; MICRORNA 182; MICRORNA 18A; MICRORNA 200B; MICRORNA 21; MICRORNA 22; MICRORNA 222; MICRORNA 34A; MICRORNA 7; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 4; UNCLASSIFIED DRUG; WNT1 PROTEIN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN RNA BINDING; STOMACH CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WNT SIGNALING PATHWAY;

EID: 84883828331     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2020.07.001     Document Type: Erratum

References (58)

1. Hartgrink H.H., Jansen E.P., van Grieken N.C., van de Velde C.J. Gastric cancer. Lancet 2009, 374:477-490.
2. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006, 24:2137-2150.
3. Filomeni G., Aquilano K., Rotilio G., Ciriolo M.R. Glutathione-related systems and modulation of extracellular signal-regulated kinases are involved in the resistance of AGS adenocarcinoma gastric cells to diallyl disulfide-induced apoptosis. Cancer Res. 2005, 65:11735-11742.
4. Filomeni G., Aquilano K., Rotilio G., Ciriolo M.R. Reactive oxygen species-dependent c-Jun NH2-terminal kinase/c-Jun signaling cascade mediates neuroblastoma cell death induced by diallyl disulfide. Cancer Res. 2003, 63:5940-5949.
5. Nakagawa H., Tsuta K., Kiuchi K., Senzaki H., Tanaka K., Hioki K., Tsubura A. Growth inhibitory effects of diallyl disulfide on human breast cancer cell lines. Carcinogenesis 2001, 22:891-897.
6. Altonsy M.O., Habib T.N., Andrews S.C. Diallyl disulfide-induced apoptosis in a breast-cancer cell line (MCF-7) may be caused by inhibition of histone deacetylation. Nutr. Cancer 2012, 64:1251-1260.
7. Xiao D., Pinto J.T., Gundersen G.G., Weinstein I.B. Effects of a series of organosulfur compounds on mitotic arrest and induction of apoptosis in colon cancer cells. Mol. Cancer Ther. 2005, 4:1388-1398.
8. Nagaraj N.S., Anilakumar K.R., Singh O.V. Diallyl disulfide causes caspase-dependent apoptosis in human cancer cells through a Bax-triggered mitochondrial pathway. J. Nutr. Biochem. 2010, 21:405-412.
9. Yuan J.P., Wang G.H., Ling H., Su Q., Yang Y.H., Song Y., Tang R.J., Liu Y., Huang C. Diallyl disulfide-induced G2/M arrest of human gastric cancer MGC803 cells involves activation of p38 MAP kinase pathways. World J. Gastroenterol. 2004, 10:2731-2734.
10. Jr. Bottone F.G., Baek S.J., Nixon J.B., Eling T.E. Diallyl disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J. Nutr. 2002, 132:773-778.
11. Lund E., Guttinger S., Calado A., Dahlberg J.E., Kutay U. Nuclear export of microRNA precursors. Science 2004, 303:95-98.
12. Kurihara Y., Watanabe Y. Arabidopsis micro-RNA biogenesis through Dicer-like 1 protein functions. Proc. Natl. Acad. Sci. USA 2004, 101:12753-12758.
13. Lee R.C., Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294:862-864.
14. Houbaviy H.B., Murray M.F., Sharp P.A. Embryonic stem cell-specific microRNAs. Dev. Cell 2003, 5:351-358.
15. Hatfield S.D., Shcherbata H.R., Fischer K.A., Nakahara K., Carthew R.W., Ruohola-Baker H. Stem cell division is regulated by the microRNA pathway. Nature 2005, 435:974-978.
16. Zhang B., Pan X., Anderson T.A. MicroRNA: a new player in stem cells. J. Cell Physiol. 2006, 209:266-269.
17. Guo H.S., Xie Q., Fei J.F., Chua N.H. MicroRNA directs mRNA cleavage of the transcription factor NAC1 to downregulate auxin signals for arabidopsis lateral root development. Plant Cell 2005, 17:1376-1386.
18. Karp X., Ambros V. Developmental biology. Encountering microRNAs in cell fate signaling. Science 2005, 310:1288-1289.
19. Kwon C., Han Z., Olson E.N., Srivastava D. MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc. Natl. Acad. Sci. USA 2005, 102:18986-18991.
20. Yin Y., Li J., Chen S., Zhou T., Si J. MicroRNAs as diagnostic biomarkers in gastric cancer. Int. J. Mol. Sci. 2012, 13:12544-12555.
21. Alvarez-Garcia I., Miska E.A. MicroRNA functions in animal development and human disease. Development 2005, 132:4653-4662.
22. Mendell J.T., Olson E.N. MicroRNAs in stress signaling and human disease. Cell 2012, 148:1172-1187.
23. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
24. Jiang J., Gusev Y., Aderca I., Mettler T.A., Nagorney D.M., Brackett D.J., Roberts L.R., Schmittgen T.D. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res. 2008, 14:419-427.
25. Zhang P., Bill K., Liu J., Young E., Peng T., Bolshakov S., Hoffman A., Song Y., Demicco E.G., Terrada D.L., Creighton C.J., Anderson M.L., Lazar A.J., Calin G.G., Pollock R.E., Lev D. MiR-155 is a liposarcoma oncogene that targets casein kinase-1alpha and enhances beta-catenin signaling. Cancer Res. 2012, 72:1751-1762.
26. Majid S., Dar A.A., Saini S., Arora S., Shahryari V., Zaman M.S., Chang I., Yamamura S., Tanaka Y., Deng G., Dahiya R. MiR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 2012, 72:6435-6446.
27. Mateescu B., Batista L., Cardon M., Gruosso T., de Feraudy Y., Mariani O., Nicolas A., Meyniel J.P., Cottu P., Sastre-Garau X., Mechta-Grigoriou F. MiR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat. Med. 2011, 17:1627-1635.
28. Liu Y.N., Yin J.J., Abou-Kheir W., Hynes P.G., Casey O.M., Fang L., Yi M., Stephens R.M., Seng V., Sheppard-Tillman H., Martin P., Kelly K. MiR-1 and miR-200 inhibit EMT via slug-dependent and tumorigenesis via slug-independent mechanisms. Oncogene 2013, 32:296-306.
29. Darido C., Georgy S.R., Wilanowski T., Dworkin S., Auden A., Zhao Q., Rank G., Srivastava S., Finlay M.J., Papenfuss A.T., Pandolfi P.P., Pearson R.B., Jane S.M. Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer Cell 2011, 20:635-648.
30. Tang H., Wang Z., Liu X., Liu Q., Xu G., Li G., Wu M. LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. Curr. Cancer Drug Targets 2012, 12:1032-1042.
31. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
32. Li C., Feng Y., Coukos G., Zhang L. Therapeutic microRNA strategies in human cancer. AAPS J. 2009, 11:747-757.
33. Cui L., Zhang X., Ye G., Zheng T., Song H., Deng H., Xiao B., Xia T., Yu X., Le Y., Guo J. Gastric juice microRNAs as potential biomarkers for the screening of gastric cancer. Cancer 2013.
34. Li B.S., Zhao Y.L., Guo G., Li W., Zhu E.D., Luo X., Mao X.H., Zou Q.M., Yu P.W., Zuo Q.F., Li N., Tang B., Liu K.Y., Xiao B. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One 2012, 7:e41629.
35. Liu H., Zhu L., Liu B., Yang L., Meng X., Zhang W., Ma Y., Xiao H. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2012, 316:196-203.
36. Wang M., Gu H., Wang S., Qian H., Zhu W., Zhang L., Zhao C., Tao Y., Xu W. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol. Med. Rep. 2012, 5:1514-1520.
37. Xia J., Wu Z., Yu C., He W., Zheng H., He Y., Jian W., Chen L., Zhang L., Li W. MiR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J. Pathol. 2012, 227:470-480.
38. Li Z., Cao Y., Jie Z., Liu Y., Li Y., Li J., Zhu G., Liu Z., Tu Y., Peng G., Lee D.W., Park S.S. MiR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. Cancer Lett. 2012, 323:41-47.
39. Deng H., Guo Y., Song H., Xiao B., Sun W., Liu Z., Yu X., Xia T., Cui L., Guo J. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene 2013.
40. Bou K.T., Futoma-Kazmierczak E., Jacobsen A., Krogh A., Bardram L., Hother C., Gronbaek K., Federspiel B., Lund A.H., Friis-Hansen L. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. J. Mol. Cancer 2011, 10:29.
41. Tie Y., Pan L., Zhao K., Wu J., Liu S., Sun X., Guo B., Wang Y., Gang Y., Zhang Q., Li T., Qiao Q., Zhao Y., Nie Y., Fan D. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010, 6:e1000879.
42. Zhang Z., Liu S., Shi R., Zhao G. MiR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition. Cancer Genet. 2011, 204:486-491.
43. Hashiguchi Y., Nishida N., Mimori K., Sudo T., Tanaka F., Shibata K., Ishii H., Mochizuki H., Hase K., Doki Y., Mori M. Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int. J. Oncol. 2012, 40:1477-1482.
44. Li J., Liang S., Jin H., Xu C., Ma D., Lu X. Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells. Oncol. Rep. 2012, 27:1835-1842.
45. Yamakuchi M., Yagi S., Ito T., Lowenstein C.J. MicroRNA-22 regulates hypoxia signaling in colon cancer cells. PLoS One 2011, 6:e20291.
46. Ling B., Wang G.X., Long G., Qiu J.H., Hu Z.L. Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J. Cancer Res. Clin. Oncol. 2012, 138:1355-1361.
47. Yoshimoto N., Toyama T., Takahashi S., Sugiura H., Endo Y., Iwasa M., Fujii Y., Yamashita H. Distinct expressions of microRNAs that directly target estrogen receptor alpha in human breast cancer. Breast Cancer Res. Treat. 2011, 130:331-339.
48. Tsuchiya N., Izumiya M., Ogata-Kawata H., Okamoto K., Fujiwara Y., Nakai M., Okabe A., Schetter A.J., Bowman E.D., Midorikawa Y., Sugiyama Y., Aburatani H., Harris C.C., Nakagama H. Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer Res. 2011, 71:4628-4639.
49. Bar N., Dikstein R. MiR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One 2010, 5:e10859.
50. Jiang R., Deng L., Zhao L., Li X., Zhang F., Xia Y., Gao Y., Wang X., Sun B. MiR-22 promotes HBV-related hepatocellular carcinoma development in males. Clin. Cancer Res. 2011, 17:5593-5603.
51. Lim Y., Wright J.A., Attema J.L., Gregory P.A., Bert A.G., Smith E., Thomas D., Drew P.A., Khew-Goodall Y., Goodall G.J. Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem cell-like state. J. Cell Sci. 2013.
52. Peng B., Hu S., Jun Q., Luo D., Zhang X., Zhao H., Li D. MicroRNA-200b targets CREB1 and suppresses cell growth in human malignant glioma. Mol. Cell. Biochem. 2013, 379:51-58.
53. Pacurari M., Addison J.B., Bondalapati N., Wan Y.W., Luo D., Qian Y., Castranova V., Ivanov A.V., Guo N.L. The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. Int. J. Oncol. 2013.
54. Dai Y., Xia W., Song T., Su X., Li J., Li S., Chen Y., Wang W., Ding H., Liu X., Li H., Zhao Q., Shao N. MicroRNA-200b is overexpressed in endometrial adenocarcinomas and enhances MMP2 activity by downregulating TIMP2 in human endometrial cancer cell line HEC-1A cells. Nucl. Acid Ther. 2013, 23:29-34.
55. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Develop. 2008, 22:894-907.
56. Bracken C.P., Gregory P.A., Kolesnikoff N., Bert A.G., Wang J., Shannon M.F., Goodall G.J. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008, 68:7846-7854.
57. Kurashige J., Kamohara H., Watanabe M., Hiyoshi Y., Iwatsuki M., Tanaka Y., Kinoshita K., Saito S., Baba Y., Baba H. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann. Surg. Oncol. 2012, 19(Suppl 3):S656-S664.
58. Li Y., Hively W.P., Varmus H.E. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 2000, 19:1002-1009.